{"id":"placebo-to-bf-200-ala-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Crusting"},{"rate":null,"effect":"Phototoxic reaction"},{"rate":null,"effect":"Burning/pain at application site"}]},"_chembl":{"chemblId":"CHEMBL3781418","moleculeType":"Protein","molecularWeight":"3638.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BF-200 ALA is a topical prodrug that is converted to protoporphyrin IX in target cells. When exposed to red light (635 nm wavelength), protoporphyrin IX generates singlet oxygen and reactive oxygen species that cause selective destruction of dysplastic and malignant cells. This photodynamic therapy approach is used for treatment of actinic keratosis and other skin lesions.","oneSentence":"BF-200 ALA (aminolevulinic acid) gel is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy abnormal skin cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:32.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis (field treatment)"},{"name":"Non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)"}]},"trialDetails":[{"nctId":"NCT01966120","phase":"PHASE3","title":"Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)","status":"COMPLETED","sponsor":"Biofrontera Bioscience GmbH","startDate":"2013-10","conditions":"Actinic Keratosis","enrollment":87},{"nctId":"NCT02799069","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy","status":"COMPLETED","sponsor":"Biofrontera Bioscience GmbH","startDate":"2008-04","conditions":"Actinic Keratosis","enrollment":571},{"nctId":"NCT02799082","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.","status":"COMPLETED","sponsor":"Biofrontera Bioscience GmbH","startDate":"2007-12","conditions":"Actinic Keratosis","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to BF-200 ALA gel","genericName":"Placebo to BF-200 ALA gel","companyName":"Biofrontera Bioscience GmbH","companyId":"biofrontera-bioscience-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BF-200 ALA (aminolevulinic acid) gel is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy abnormal skin cells. Used for Actinic keratosis (field treatment), Non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}